Data from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Autor: Bruno Paiva, Jesus F. San-Miguel, Felipe Prosper, Carlos Panizo, Paula Rodriguez-Otero, Juana Merino, Cristina Moreno, Victor Segura, Tomas Jelinek, Sonia Garate, Idoia Rodriguez, Patricia Maiso, Marta Lasa, Laura Blanco, Daniel Ajona, Diego Alignani, Irene Manrique, Aintzane Zabaleta, Cristina Perez, Laura Moreno

Purpose:Knowledge about the mechanism of action (MoA) of monoclonal antibodies (mAb) is required to understand which patients with multiple myeloma (MM) benefit the most from a given mAb, alone or in combination therapy. Although there is considerabl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5510c21b8ecb914ea8586be75389aa51
https://doi.org/10.1158/1078-0432.c.6527141

Supplementary Figure 1 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Autor: Bruno Paiva, Jesus F. San-Miguel, Felipe Prosper, Carlos Panizo, Paula Rodriguez-Otero, Juana Merino, Cristina Moreno, Victor Segura, Tomas Jelinek, Sonia Garate, Idoia Rodriguez, Patricia Maiso, Marta Lasa, Laura Blanco, Daniel Ajona, Diego Alignani, Irene Manrique, Aintzane Zabaleta, Cristina Perez, Laura Moreno

Supplementary Figure 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a17008c0f8e05fe53f848bbc17ea0e
https://doi.org/10.1158/1078-0432.22469111

Supplementary Figure 3 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Autor: Bruno Paiva, Jesus F. San-Miguel, Felipe Prosper, Carlos Panizo, Paula Rodriguez-Otero, Juana Merino, Cristina Moreno, Victor Segura, Tomas Jelinek, Sonia Garate, Idoia Rodriguez, Patricia Maiso, Marta Lasa, Laura Blanco, Daniel Ajona, Diego Alignani, Irene Manrique, Aintzane Zabaleta, Cristina Perez, Laura Moreno

Supplementary Figure 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54334f2fd2ab6720b964a001a08d979c
https://doi.org/10.1158/1078-0432.22469105.v1

Supplementary Methods from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Autor: Bruno Paiva, Jesus F. San-Miguel, Felipe Prosper, Carlos Panizo, Paula Rodriguez-Otero, Juana Merino, Cristina Moreno, Victor Segura, Tomas Jelinek, Sonia Garate, Idoia Rodriguez, Patricia Maiso, Marta Lasa, Laura Blanco, Daniel Ajona, Diego Alignani, Irene Manrique, Aintzane Zabaleta, Cristina Perez, Laura Moreno

Supplementary Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1347955932a61db02db800c5433d9679
https://doi.org/10.1158/1078-0432.22469096

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Autor: Joaquin Martinez-Lopez, Diego Alignani, Jesús Martín-Sánchez, Norma C. Gutiérrez, Juan Flores-Montero, Ibai Goicoechea, Rafael Rios, Joan Bargay, Noemi Puig, Leire Burgos, Juan José Garcés, Maria-Victoria Mateos, Juan José Lahuerta, Joan Bladé, María-Belén Vidriales, Lourdes Cordón, Maria-Jose Calasanz, Isabel Krsnik, Bruno Paiva, Miguel-Teodoro Hernández, Albert Oriol, Sara Rodriguez, Idoia Rodriguez, Maria-Teresa Cedena, Vicente Fresquet, Luis Palomera, Sarai Sarvide, J A Martinez-Climent, Amaia Vilas-Zornoza, Alberto Orfao, Javier de la Rubia, Rafael Martínez-Martínez, Ramón García-Sanz, David Lara-Astiaso, José-María Moraleda, Jesús F. San Miguel, Laura Rosiñol, Jon Celay, Josep Sarrá, María-Luisa Martín Ramos, Daniel Alameda

Publikováno v: BLOOD
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Digital.CSIC. Repositorio Institucional del CSIC

PETHEMA/GEM Cooperative Group.
Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior progression-free survival (PFS). This qu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61b581cc3448df30b73f62e79b39dc83
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7875